How Merck’s Gardasil and Other Human Vaccines Performed in 2Q17
Merck’s (MRK) Gardasil franchise includes vaccines for the prevention of certain strains of HPV infections that are sexually transmitted.
Healthcare
The latest news in the healthcare sector including biotech and telehealth.
Inside Baxter International’s Stock Price Performance
On September 7, 2017, BAX stock closed at $62.84 per share. It has a 50-day moving average of $61.15 and a 200-day moving average of $57.14.
Where Jazz Pharmaceuticals’ Erwinaze and Prialt Are Positioned after 2Q17
In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Erwinaze generated revenues of ~$49 million, which represents a ~1% fall YoY and a ~4% fall QoQ.
Nuplazid for Long-Term Care: Revenue Driver for Acadia?
Acadia Pharmaceuticals (ACAD) plans to focus on long-term care (or LTC) facilities to boost Nuplazid’s adoption in the Parkinson’s disease (or PD) psychosis indication.
Nuplazid Sees Increasing Physician Intent to Prescribe in 2017
Acadia Pharmaceuticals’ (ACAD) commercial teams have been carrying out promotional efforts to create awareness for Nuplazid among physicians with the intent to have them prescribe the drug.
How Is Jazz’s Defitelio Positioned after 2Q17?
In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Defitelio generated revenues of ~$30 million, which represents a ~10% fall YoY and a ~17% fall QoQ.
Why Jazz Pharmaceuticals’ Vyxeos Could Boost Revenue Growth in 2018
In August 2017, JAZZ’s Vyxeos liposome injection for the treatment of adult individuals with rapidly progressing or life t-AML received FDA approval.
How Japan’s Manufacturing Activity Trended in August 2017
Japan’s manufacturing PMI stood at 52.2 in August 2017 as compared to 52.1 in July 2017.
Captisol-Enabled Prexasertib May Be Major Growth Driver for Ligand
Eli Lilly’s (LLY) Captisol-enabled drug Prexasertib is currently being evaluated in multiple oncology indications such as head and neck cancer, small-cell lung cancer (or SCLC), and advanced metastatic cancer.
Sparsentan May Be Solid Near-Term Growth Driver for Ligand
With Sparsentan, Retrophin and Ligand Pharmaceuticals could become major nephrology players similar to peers such as Amgen (AMGN), AstraZeneca (AZN), and Bristol-Myers Squibb (BMY).
This Part of Bioverativ’s Pipeline Could Be a Major Long-Term Growth Driver
In June 2017, the FDA accepted Bioverativ’s investigative new drug application for BIVV001, a drug designed to treat prophylaxis from bleeding associated with hemophilia A.
Performance of AstraZeneca’s Other Products in 2Q17
AstraZeneca’s Other Products segment’s revenues fell 12% at constant exchange rates to ~$1.1 billion during 2Q17.
How Are Bioverativ’s Key Drugs Positioned after 2Q17?
In 2Q17, Bioverativ’s Alprolix generated revenues of ~$89.7 million, which represents ~12% growth YoY (year-over-year) and ~4% growth sequentially.
Eli Lilly & Co.’s Recent Developments after Its 2Q17 Earnings
On July 31, 2017, Eli Lilly and Boehringer Ingelheim announced that the companies would support one of the new programs by the American College of Cardiology.
Performance of AstraZeneca’s Growth Platforms in 2Q17
Emerging markets such as China, Brazil, India, Russia, Mexico, and Turkey reported revenues of ~$1.4 billion during 2Q17, representing 2% growth at constant exchange rates from 2Q16.
Boston Scientific’s Updated 2017 Guidance
Boston Scientific (BSX) expects to register 2017 revenues of $8.9 billion–$9.0 billion compared to its previous guidance of $8.8 billion–$8.9 billion.
Performance of Eli Lilly’s Neuroscience Products in 2Q17
Cymbalta’s sales totaled $206.6 million during 2Q17, a 13.0% decline compared to sales of $236.5 million in 2Q16.
Medtronic’s Robust Product Pipeline
On May 1, 2017, Medtronic announced the FDA approval of its Resolute Onyx DES (drug eluting stent) for adult patients suffering from coronary artery disease.
Boston Scientific Is Accelerating Category Leadership Strategy
Boston Scientific (BSX) currently has a global market opportunity of $40.0 billion, which is expected to grow to $50.0 billion by fiscal 2020.
What’s behind Medtronic’s Accelerating Margin Expansion?
In fiscal 1Q18, Medtronic (MDT) reported ~26.9% of operating margin on a constant currency basis. This represented year-over-year growth of ~50 basis points.
Intuitive Surgical Plans to Expand in Europe and Asia
Although Intuitive Surgical leads the surgical robotics market, there are competitive threats from other major players in the market.
Performance of Eli Lilly’s Endocrine Franchise in 2Q17
Forteo is used for the treatment of osteoporosis. Forteo’s sales totaled $446.7 million during 2Q17, a 22.0% increase compared to $367.6 million in 2Q16.
Divestiture of a Part of Medtronic’s PMR Business to Cardinal Health
Medtronics’ MITG (Minimally Invasive Therapies Group) business is expected to grow 3.5%–4.5%.
Ligand Pharmaceuticals Projects Higher Average Royalty Rate for Promacta
Ligand Pharmaceuticals (LGND) receives royalties from Novartis on Promacta’s sales according to a tiered annual payment structure.
How Pfizer’s Enbrel and Xeljanz Are Positioned after 2Q17
In August 2017, the Arthritis Advisory Committee of the FDA recommended a positive opinion for the proposed dose of Xeljanz for the treatment of individuals with active psoriatic arthritis.
How Medtronic Is Delivering on Its Covidien Synergies
In January 2015, Medtronic (MDT) acquired Covidien for ~$43 billion in cash and MDT stock in a tax inversion deal.
Promacta: A Major Growth Driver for Ligand Pharmaceuticals in 2017
Promacta was discovered by Ligand Pharmaceuticals (LGND) and GlaxoSmithKline (GSK) as a part of their thrombopoietin (or TPO) receptor agonist research collaboration.
Medtronic’s Emerging Market Position and Opportunities for Fiscal 2018
Medtronic (MDT) registered revenues of ~$1.0 billion revenues from emerging markets in fiscal 1Q18, which represents YoY (year-over-year) sales growth of ~11% in that market.
What Do Westlake Chemical’s Valuations Suggest?
Westlake Chemical is trading at a premium to its peer Eastman Chemical. After good earnings in 1H17, analysts expect Westlake Chemical to post EPS of $4.66.
A Post-2Q17 Look at Pfizer’s Internal Medicines
In 2Q17, Chantix/Champix generated revenues of ~$248 million, which represents ~16% growth on a YoY basis and 4% growth on a quarter-over-quarter basis.
Eli Lilly’s Valuations after Its 2Q17 Earnings
Eli Lilly (LLY) surpassed Wall Street estimates in 2Q17, reporting earnings per share of $1.11 on revenues of ~$5.8 billion. Analysts estimated that the company would report EPS of $1.05 on revenues of $5.6 billion.
Stryker Stock Falls Due to the Impact of the Sage Products Recall
On August 23, Stryker (SYK) announced a voluntary product recall of specific lots of oral care products that form part of the company’s Sage business unit.
What Zimmer Biomet’s Leadership Transition Could Mean for Its Core Growth Strategy
In July 2017, David Dvorak stepped down as chief executive officer and president of Zimmer Biomet (ZBH) and resigned from its board of directors.
GlaxoSmithKline Reported Revenue Growth in 2Q17
GlaxoSmithKline (GSK) reported revenues of 7.32 billion pounds in 2Q17—12% growth compared to revenues of 6.53 billion pounds in 2Q16.
Changes in GlaxoSmithKline’s Valuation after 2Q17
As of August 30, 2017, GlaxoSmithKline is trading at a forward PE multiple of 13.3x, which is slightly lower than the industry average of 15.5x.
How United Therapeutics’ Remodulin and Tyvaso Are Performing
In 2Q17, United Therapeutics’ (UTHR) Remodulin generated revenues of around $158 million, which reflected ~8% growth on a quarter-over-quarter basis.
How Medtronic Is Accelerating Its Economic Value Growth Strategy
Medtronic’s (MDT) Hospital Solutions segment registered double-digit growth in fiscal 1Q18.
How Did United Therapeutics’ Orenitram and Unituxin Perform in 2Q17?
In 2Q17, United Therapeutics’ (UTHR) Unituxin generated revenues of around $16 million, a 10% decline on a year-over-year (or YoY) basis and an 11% decline on a quarter-over-quarter basis.
Fully Funded Partnerships May Drive Growth for Ligand Pharmaceuticals
Ligand Pharmaceuticals (LGND) expects its licensees to invest ~$2.0 billion for advancing more than 155 partnered research and development programs in 2017.
How Novartis’s Sandoz Performed in 2Q17
Novartis’s Sandoz reported revenues of nearly $2.5 billion in 2Q17, representing ~20% of NVS’s total revenues.
Bristol-Myers Squibb’s Immunoscience Products in 2Q17
Orencia revenues rose to $650.0 million in 2Q17, a 10.0% rise compared to $593 million in 2Q16.
What Happened to Novartis’s Innovative Medicines Business in 2Q17?
Novartis’s Innovative Medicines segment contributed over 67% of NVS’s total revenues at nearly $8.3 billion for the quarter.
Inside Novartis’s 2Q17 Revenues
Novartis (NVS) reported flat revenues of $12.24 billion on a constant-currency basis for 2Q17. This included a 2% decline due to foreign exchange.
Talazoparib Could Be a Significant Long-Term Growth Driver for Pfizer
In June 2017, Pfizer (PFE) presented the results from the Phase 2 ABRAZO trial.
Bristol-Myers Squibb’s Virology Products in 2Q17
Bristol-Myers Squibb’s (BMY) virology products portfolio includes products for the treatment of chronic virus infections.
Major Developments for Johnson & Johnson in 2Q17
Major developments All of Johnson & Johnson’s (JNJ) segments performed positively in 2Q17. In this part. we’ll look at some developments that occurred during the quarter. Pharmaceuticals On August 21, 2017, Johnson & Johnson presented new data for its COMPASS study, a phase III study evaluating Xarelto as a treatment for coronary and peripheral artery disease. […]
Johnson & Johnson’s Medical Devices Segment in 2Q17
Medical devices segment Johnson & Johnson’s (JNJ) medical devices segment reported revenue of $6.7 billion in 2Q17, a growth of 4.9% from the revenue of $6.4 billion reported in 2Q16. This figure included 5.9% growth in operating revenue, and was partially offset by a 1% foreign exchange impact. Cardiovascular care franchise The cardiovascular care franchise […]
Bristol-Myers Squibb’s Revenues in 2Q17
Bristol-Myers Squibb (BMY) surpassed Wall Street analysts’ estimate for 2Q17 revenues, reporting $5.14 billion compared to the estimate of $5.09 billion.
Bristol-Myers Squibb’s Valuation after 2Q17 Earnings
Bristol-Myers Squibb (BMY) met Wall Street analysts’ estimate for EPS at $0.74. It also surpassed the estimates for revenues.
How Is Becton Dickinson Progressing with Emerging Market Growth?
Becton Dickinson’s (BDX) emerging markets registered a strong double-digit growth of 10.9% in 3Q17.